Welcome to our dedicated page for Alpine Immune Sciences news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences stock.
Founded in 2015, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a leading clinical-stage biotechnology company dedicated to developing innovative protein-based immunotherapies to treat autoimmune and inflammatory diseases. Alpine leverages its unique understanding of immunology, particularly recombinant protein-based immunotherapies, to modify the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Alpine's standout product, povetacicept (ALPN-303), is a dual antagonist of the BAFF and APRIL cytokines. This product is currently in phase 2 development and has demonstrated potential best-in-class efficacy for treating IgA nephropathy (IgAN). IgAN is a serious, progressive kidney disease with no approved therapies that target its underlying cause. Povetacicept has exhibited promising results in reducing proteinuria, stabilizing renal function, and reducing key disease-related biomarkers.
Additionally, Alpine has a robust pipeline, including acazicolcept (ALPN-101), a first-in-class dual inhibitor targeting the CD28 and ICOS T-cell costimulatory pathways. This drug is being investigated for treating systemic lupus erythematosus (SLE) and other autoimmune diseases. Alpine's research and development capabilities are enhanced by strategic collaborations with leading global biopharmaceutical companies, propelling its efforts to create multifunctional immunotherapies that improve patients' lives.
The company has been highly productive in the past year, achieving significant milestones, such as the phase 2 study of acazicolcept in SLE, a pivotal phase 3 trial of povetacicept in IgAN planned for the second half of 2024, and successful financial activities supporting ongoing and future development projects.
Alpine Immune Sciences remains committed to innovation, with ongoing studies in various autoimmune diseases and strategic goals aligning with its mission to lead a new wave of immune therapeutics.
Alpine Immune Sciences (NASDAQ: ALPN) reported a transformative year in 2020, focusing on innovative therapies for cancer and autoimmune diseases. They plan to initiate an international Phase 2 trial for ALPN-101 in systemic lupus erythematosus and continue their Phase 1 study for ALPN-202. The company raised $60 million from a private placement and formed an exclusive license agreement with AbbVie for ALPN-101, potentially worth $805 million. Financially, they reported $131.4 million in cash and a rise in collaboration revenue to $9.3 million, while net losses decreased from $41.9 million in 2019 to $27.9 million in 2020.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will release its fourth quarter and full year 2020 financial results on March 18, 2021, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors can access the call via phone or through a webcast on the company's investor relations page. A replay will be available for 90 days post-event. Alpine aims to lead in immunotherapy with a strong R&D platform and collaborations in the biopharmaceutical sector.
Alpine Immune Sciences (NASDAQ:ALPN) announced its participation in the AACR Virtual Annual Meeting I, scheduled for April 10-15, 2021. The company will present two posters: one on the Phase 1 NEON-1 study of ALPN-202, a dual checkpoint inhibitor for advanced malignancies, and another detailing a preclinical study on engineered fusion proteins for anti-tumor immunity. ALPN-202 aims to enhance checkpoint inhibition effectiveness while minimizing toxicities, with promising preclinical efficacy demonstrated.
Alpine Immune Sciences (NASDAQ:ALPN) has announced its participation in three upcoming virtual healthcare conferences. The events include the Cowen 41st Annual Virtual Health Care Conference on March 1, 2021, featuring a Novel IO Panel at 10:20 a.m. ET; the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, with an on-demand company presentation starting at 7:00 a.m. ET; and the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021, at 1:50 p.m. ET. Webcasts of the presentations will be available for 90 days online.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has appointed Pamela Holland, Ph.D., as Senior Vice President of Research. Dr. Holland brings extensive experience in cancer biology, crucial for advancing the company’s immunotherapy portfolio, including ALPN-101 and ALPN-202. Additionally, Remy Durand, Ph.D., has been promoted to Chief Business Officer, playing a key role in corporate strategy and partnerships. Both appointments aim to strengthen and accelerate the research and development efforts at Alpine, positioning the company for significant advancements in 2021.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a clinical-stage immunotherapy company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:00 p.m. ET. The presentation will highlight their innovative treatments for cancer and autoimmune diseases. A live webcast can be accessed in the investor relations section of their website, with a replay available for 90 days post-event. Alpine is recognized for its unique protein engineering technologies aimed at developing first- or best-in-class immunotherapies.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has appointed Natasha A. Hernday to its Board of Directors. With over 20 years of experience in corporate development, including her role at Seagen, Hernday's expertise is expected to enhance Alpine's strategic direction. This leadership change coincides with Paul Sekhri stepping down from his board position after serving since February 2016. Executive Chairman Mitchell H. Gold emphasized the timing of this transition as vital for advancing Alpine's pipeline and building on its partnership with AbbVie.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference, scheduled for December 3, 2020, at 4:45 p.m. ET. Members of the senior leadership team will engage in an analyst-led fireside chat. Investors can access a live webcast through the company’s investor relations website, with a replay available for 90 days after the event. Alpine focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases, leveraging unique protein engineering technologies.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place from December 1-3, 2020. The event will include a fireside chat, accessible online during the week of November 23 via the company's investor relations webpage. Alpine is focused on developing immunotherapies for cancer and autoimmune diseases, leveraging innovative protein engineering technologies to enhance patient care.
Alpine Immune Sciences (NASDAQ:ALPN) reported its Q3 2020 results, highlighting a revenue increase to $1.9 million, up from $0.3 million in Q3 2019. The company successfully raised $60 million in a private placement, enhancing its cash position to $141.3 million. Key developments include preparations for a Phase 2 study of ALPN-101 for systemic lupus erythematosus and ongoing enrollment in a Phase 1 study for ALPN-202. Despite a net loss of $6.1 million in Q3 2020, sufficient funds are projected to support operations into 2024.
FAQ
What is the current stock price of Alpine Immune Sciences (ALPN)?
What is the market cap of Alpine Immune Sciences (ALPN)?
What does Alpine Immune Sciences, Inc. specialize in?
What is povetacicept (ALPN-303)?
What are the core focus areas of Alpine Immune Sciences?
What recent achievement has Alpine Immune Sciences accomplished?
What is acazicolcept (ALPN-101)?
What collaborations has Alpine Immune Sciences engaged in?
What is the ticker symbol for Alpine Immune Sciences?
When was Alpine Immune Sciences founded?
What is the mission of Alpine Immune Sciences?
Where can more information about Alpine Immune Sciences be found?
